{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-089949","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.262236+00:00","generated_at":"2026-05-18T19:13:31.566600+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Assembly Bio reports positive Phase 1b topline results for ABI-4334 in chronic HBV; Gilead opt-in triggered","bullets":["Mean HBV DNA decline of 3.2 log10 IU/mL over 28 days in 400 mg cohort (2.9 logs in 150 mg cohort).","Favorable safety: no serious AEs or discontinuations; two grade 3 lab abnormalities resolved with continued dosing.","Half-life supports once-daily oral dosing; exposure at both doses achieved double-digit multiples over target EC50.","Data triggers Gilead's right to opt-in for exclusive license after review of option data package.","ABI-4334 shows potential to inhibit viral replication at 150 mg and cccDNA formation at higher doses."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-089949","json":"https://secwatch.observer/filing/0000950170-25-089949.json","markdown":"https://secwatch.observer/filing/0000950170-25-089949.md","text":"https://secwatch.observer/filing/0000950170-25-089949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017025089949/0000950170-25-089949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017025089949/asmb-20250625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:13:31.566600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}